Neuroone Medical Technologies (NMTC) Return on Capital Employed (2011 - 2026)

Neuroone Medical Technologies has disclosed Return on Capital Employed across 15 years of filings, most recently posting 115.33% for Q1 2026.

• Quarterly Return on Capital Employed rose 6191.0% year-over-year to 115.33% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 115.33% (up 6191.0% YoY) and the FY2025 annual result came in at 73.19%, up 18978.0% from the prior year.
• Return on Capital Employed slipped to 115.33% in Q1 2026, from 90.76% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 49.73% in Q3 2025 and bottomed at 405.98% in Q3 2024.
• The 5-year median for Return on Capital Employed is 137.19% (2023), against an average of 174.06%.
• Year-over-year, Return on Capital Employed slumped 18117 bps in 2024 and soared 35625 bps in 2025.
• Neuroone Medical Technologies' Return on Capital Employed stood at 90.91% in 2022, then sank by 168 bps to 243.18% in 2023, then jumped by 36 bps to 155.59% in 2024, then jumped by 42 bps to 90.76% in 2025, then retreated by 27 bps to 115.33% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 115.33%, 90.76%, and 49.73% for Q1 2026, Q4 2025, and Q3 2025 respectively.